A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

NCT03768960 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab

Sponsor

Johnson & Johnson Private Limited